NewsOct 20, 2026, 9:47 PM UTC#BIO

OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work

The ChatGPT maker is folding Orchestra’s drug-program agents into Rosalind, its life sciences suite, betting AI can shave time off the decade-plus it takes to bring a medicine to patients.

Related market data

BIO: price 0.02469, 24h 5.37%, funding 0.0013%/h, OI $890.2K

Read the full story at decrypt.co: https://decrypt.co/381467/openai-buys-orchestra-bio-ai-agents-drug-development

Source: decrypt.co

BIO price and whales

People Are Vibe Coding the Ads Out of Their Smart TVs: Here's How10/20, 22:17
Utah AG sues Kalshi, pursues profits from prediction market company10/20, 21:26
JPMorgan Puts a Number on Bitcoin for the First Time: 10% a Year, With a Big Caveat10/20, 21:17
U.S. CFTC sets agenda for AI forum, exploring trading and agentic finance10/20, 21:13
Wallet Linked to Drift Exploit Sends $61 Million in Ethereum to Tornado Cash10/20, 20:47
Bitwise, Hyperliquid seek SEC rule changes for token trading, airdrops10/20, 20:46

Information on Whale Radar is for reference only and is not investment advice. Leveraged derivatives trading can cost you your entire capital.

OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work

Related market data

More posts